Clinical Review Criteria

Autologous Chondrocyte (Carticel®) Implantation for Treatment of Defects in Articular Cartilage of the Knee

NOTICE: Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc., provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. Member contracts differ in their benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Customer Service to determine coverage for a specific medical service.

Criteria

For Medicare Members

<table>
<thead>
<tr>
<th>Source</th>
<th>Policy</th>
</tr>
</thead>
<tbody>
<tr>
<td>CMS Coverage Manuals</td>
<td>None</td>
</tr>
<tr>
<td>National Coverage Determinations (NCD)</td>
<td>None</td>
</tr>
<tr>
<td>Local Coverage Determinations (LCD)</td>
<td>None</td>
</tr>
<tr>
<td>Local Coverage Article</td>
<td>None</td>
</tr>
<tr>
<td>KPWA Medical Policy</td>
<td>Due to the absence of a NCD, LCD, or other coverage guidance, KPWA has chosen to use their own Clinical Review Criteria, “Autologous Chondrocyte Implantation,” for medical necessity determinations. Use the Non-Medicare criteria below.</td>
</tr>
</tbody>
</table>

For Non-Medicare Members

Kaiser Permanente has elected to use the Autologous Chondrocyte Implantation (A-0415) MCG* for medical necessity determinations. Per MCG guideline this is a non-covered service.

*MCG manuals are proprietary and cannot be published and/or distributed. However, on an individual member basis, Kaiser Permanente can share a copy of the specific criteria document used to make a utilization management decision. If one of your patients is being reviewed using these criteria, you may request a copy of the criteria by calling the Kaiser Permanente Clinical Review staff at 1-800-289-1363.

If requesting this service, please send the following documentation to support medical necessity:

- Last 6 months of clinical notes from requesting provider &/or specialist

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, KPWA will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

Background

Articular hyaline cartilage is a highly specialized connective tissue that covers the surface of bone in synovial joints. It is a 2-4mm thick hyaline cartilage that provides smooth low friction movement and shock absorption. Unlike most tissues, articular cartilage does not have blood vessels, nerves, or lymphatics. It is composed of a dense extracellular matrix (ECM) with a sparse distribution of highly specialized cells called chondrocytes. The ECM is principally composed of water, collagen, and proteoglycans, with other non-collagenous proteins and glycoproteins present in lesser amounts. These components help to retain water within the ECM, which is critical to maintain the unique mechanical properties of the cartilage (Fox 2009, Negrin 2013, Oussedik 2015).

The articular cartilage is prone to damage from acute high energy trauma and from repetitive shear and torsional forces applied to the surface. Lesions to the articular cartilage are often associated with pain and compromised
Autologous chondrocyte implantation (ACI) is a cell-based method that was introduced in the late 1980s for the treatment of symptomatic full thickness cartilage defects of the knee. The first generation of ACI (ACI-P) is a two-stage procedure. First, a cartilage biopsy is harvested from healthy cartilage of the affected knee during an arthroscopic biopsy procedure. The specimen of live articular cartilage is sent to a cell expansion laboratory for chondrocyte culture. The cells are separated from the cartilage under a strictly controlled environment, and then multiplied using a cell-culture technique for 3-6 weeks. The cultured chondrocytes are then implanted into the cartilage defect in an open arthrotomy procedure. This procedure involves removing a periosteal flap from the proximal medial tibia, suturing it to the surrounding rim of normal tissue, and implanting the expanded chondrocytes beneath the flap to start filling the defect by producing a matrix. Unlike the MS techniques, it is reported that ACI has the ability of repairing the defect by a hyaline-like cartilage with a hybrid of fibrocartilage and hyaline-like tissue, or with fibrocartilaginous material containing type-I and type-II collagen. ACI-P is an invasive, technically complicated procedure that involves two operations, has a long recovery time, and requires extensive post-surgical rehabilitation. The technique has variable success rate and may be associated with periosteal hypertrophy and overgrowth that would require additional surgeries (Crawford 2012, Niemeyer 2014, Mundi 2015).

Several modifications to the first generation ACI-P have been made to reduce the procedural technical demands associated with the tissue harvest and the use of periosteal flap in order to decrease the surgical morbidity and prevent periosteal hypertrophy and overgrowth. These modifications were described as second and third generations. The second generation ACI (ACI-C) uses bioengineered bilayer collagen covers to substitute for the periosteal flap and avoid the spill over and asymmetric distribution of chondrocytes following implantation. The third generation ACI explores the use of biomaterials to construct a 3-dimensional scaffold for chondrocyte implantation; the all-in-one grafts do not need a periosteal cover or fixing stitches and can be trimmed to fit the cartilage defect with fibrin glue. It has been reported that implantation of third generation ACI can be performed arthroscopically or with a small incision (Vasiliadis 2010, Kuroda 2011, Crawford 2012, Negrin 2013, Mundi 2015, Samsudin 2015).
**Evidence Conclusion:** The existing evidence is not sufficient to determine the effect of ACI on health outcomes. The only data available are from case series reports that have compromised validity and are not considered to provide high-quality data. Each of the two case series articles evaluated had additional limitations beyond study type including providing little information about possible adverse effects. Peterson and colleagues are involved with a prospective randomized trial of autologous chondrocyte transplantation compared to periosteum alone or subchondral drilling for the treatment of primary chondral lesions of the femoral condyle. Results of this study will provide higher-quality data.

**Articles:** Fourteen articles were identified. Eleven articles were not directly relevant, did not include clinical outcomes or were review articles; three articles presented empirical data on clinical outcomes. Articles were selected based on study type. There were no meta-analyses or randomized controlled trials. The three empirical articles were all case series. Sample sizes were 8 patients, 44 patients and 94 patients. An evidence table was created for the two case series reports with the largest number of patients: Peterson L, Minas T, Brittberg M, Nilsson A, Sjogren-Jansson E, Lindahl, A. Two-to-9 year outcome after autologous chondrocyte transplantation of the knee: Clin Orthop 2000; 374: 212-234. See Evidence Table. Minas T. Chondrocyte implantation in the repair of chondral lesions of the knee: Economics and quality of life. Am J Orthop 1998; 27: 739-44. See Evidence Table.

The use of Autologous Chondrocyte (Carticel®) Implantation for Treatment of Defects in Articular Cartilage of the Knee does not meet the Kaiser Permanente Medical Technology Assessment Criteria.

**04/17/2003: MTAC REVIEW**  
**Autologous Chondrocyte Implantation**

**Evidence Conclusion:** There were two small randomized controlled trials (Bentley et al, n=100.; Horas et al., n=40). Neither provided strong evidence that autologous chondrocyte implantation is superior to an alternate procedure for repairing osteochondral defects in the knee. The Bentley study was larger and had stronger methodology. The authors found that the overall clinical results did not differ significantly between groups (autologous chondrocyte implantation compared to mosaicplasty), but that, among the 51 patients with medial femoral defects, the autologous chondrocyte group had better post-operative knee function. The one-year arthroscopic data in the Bentley study was compromised because 40% of patients were missing from the analysis. The Horas study had inadequate randomization and several additional threats to validity. They found worse post-operative knee instability in the autologous chondrocyte transplantation group compared to a group receiving autologous osteochondral cylinder transplantation and no significant differences between groups on the two other primary measures.


The use of Autologous Chondrocyte (Carticel®) Implantation for Treatment of Defects in Articular Cartilage of the Knee does not meet the Kaiser Permanente Medical Technology Assessment Criteria.

**07/14/2004: MTAC REVIEW**  
**Autologous Chondrocyte Implantation**

**Evidence Conclusion:** The evidence consists of three controlled trials (2 randomized, 1 pseudo-randomized), all comparing autologous chondrocyte implantation to other surgical procedures to restore articular cartilage. There are no sham controlled studies. None of the studies found significantly better clinical outcomes with ACI compared to the alternative intervention 1-2 years post-surgery; some may have been underpowered. Knutsen et al, the strongest study methodologically, found better results for the group receiving microfracture on one key outcome, the physical component score of the SF-36. The Bentley study found better histological results in the ACI group, the strongest study methodologically, found better results for the group receiving microfracture on one key outcome, the physical component score of the SF-36. The Bentley study found better histological results in the ACI group, but that, among the 51 patients with medial femoral defects, the autologous chondrocyte group had better post-operative knee function. The one-year arthroscopic data in the Bentley study was compromised because 40% of patients were missing from the analysis. The Bentley study had inadequate randomization and several additional threats to validity. They found worse post-operative knee instability in the autologous chondrocyte transplantation group compared to a group receiving autologous osteochondral cylinder transplantation and no significant differences between groups on the two other primary measures.

**Articles:** The Medline search yielded 42 articles, many of which were on technical aspects of the procedure or on related technologies. There were three randomized controlled trials and all three were critically appraised. References are as follows: Knutsen G, Engebretsen L, Ludvigsen TC. Autologous chondrocyte implantation compared with microfracture in the knee. J Bone Joint Surg 2004; 86-A: 455-464. See Evidence Table.

The use of Autologous Chondrocyte (Carticel®) Implantation for Treatment of Defects in Articular Cartilage of the Knee does not meet the Kaiser Permanente Medical Technology Assessment Criteria.

**06/05/2006: MTAC REVIEW**

© 1998 Kaiser Foundation Health Plan of Washington. All Rights Reserved.
Autologous Chondrocyte Implantation

Evidence Conclusion: One new RCT compared autologous chondrocyte implantation to an alternative procedure. The study (Dozín et al., 2005) did not find a significant difference in the clinical success rate of patients who received ACI or mosaicplasty. The study was underpowered to detect a clinically meaningful difference between groups due to low compliance rate. Only 12/22 (54%) in the ACI group and 11/22 (50%) in the mosaicplasty group actually received the surgery, which occurred 6 months after an initial debridement. The best evidence on ACI for treatment of defects in articular cartilage of the knee remains the randomized controlled trials reviewed in 2004. The conclusion from the previous MTAC report was: The evidence consists of three controlled trials (2 randomized, 1 pseudo-randomized), all comparing autologous chondrocyte implantation to other surgical procedures to restore articular cartilage. There are no sham controlled studies. None of the studies found significantly better clinical outcomes with ACI compared to the alternative intervention 1-2 years post-surgery; some may have been underpowered. Knutsen et al, the strongest study methodologically, found better results for the group receiving microfracture on one key outcome, the physical component score of the SF-36. The Bentley study found better histological results in the ACI group, but this analysis included only 60% of the randomized patients. In summary, ACI does not provide a clear clinical advantage over other surgical procedures to heal cartilage injuries and may be inferior to microfracture. A 2005 technology assessment conducted by the National Institute for Health and Clinical Effectiveness (NICE) in England concluded that there is inconsistent evidence on the clinical effectiveness of ACI and did not recommend ACI except in the context of ongoing clinical trials.

Articles: Three new randomized controlled trials were identified. Two trials, one by Bartlett and colleagues and the other by Gooding and colleagues, were not evaluated further because they compared two types of autologous chondrocyte replacement and did not include a control group that received an intervention other than ACI. (In addition, the Gooding study was only available as an abstract). The other trial compared ACI and mosaicplasty and was critically appraised: Dozín B, Malpeli M, Cancella R et al. Comparative evaluation of autologous chondrocyte implantation and mosaicplasty. Clin J Sport Med 2005; 15: 220-226. See Evidence Table.

The use of Autologous Chondrocyte (Carticel®) Implantation for Treatment of Defects in Articular Cartilage of the Knee does not meet the Kaiser Permanente Medical Technology Assessment Criteria.

03/21/2016: MTAC REVIEW

Autologous Chondrocyte Implantation (Autologous Chondrocyte Transplantation) For the Treatment of Chondral Defects in the Knee

Evidence Conclusion: Autologous chondrocyte Implantation (Carticel, the first generation) was previously reviewed by MTAC, four times between 1998 and 2006. At the time the best published evidence consisted of four controlled trials (three randomized and one pseudo-randomized), none of which found significantly better clinical outcomes with ACI compared to the alternative interventions at 1-2 years post-surgery. Knutsen et al (2004), the strongest study methodologically, at the time, found better results for the group receiving microfracture on one key outcome (the physical component score of the SF-36). The Bentley et al’s study (2003) found better histological results in the ACI group, but the analysis included only 60% of the randomized patients. In summary the 2006 report concluded that ACI does not provide a clear clinical advantage over other surgical procedures to heal cartilage injuries and may be inferior to microfracture. The updated literature search for the current re-review of ACI, identified a number of published comparative and non-comparative studies evaluating the effectiveness of ACI, marrow stimulation (MS, mainly with MF techniques), and OAT, in improving the clinical outcomes of patients with cartilage lesions in the knee. Different ACI generations and techniques were evaluated and/or compared to other interventions used for restoring knee function. The published studies were relatively small, and in addition to the variations in the surgical techniques and approaches used for ACI and other procedures, there were differences between the studies in the criteria for patient selection, lesion sizes, outcomes, duration of follow-up, and measures used to evaluate histological and/or functional outcomes. In addition none of the trials was blinded and pain and function measures mainly relied on subjective evaluation, which may bias the results. Few studies showed minimal differences between ACI compared to MF, or OAT, and many others found no significant differences in outcomes with the different surgical techniques. The majority of the studies were underpowered to detect statistical differences, and a lack of significant differences between procedures does not necessarily indicate that they are equivalent or have similar effects. Combining the studies into meta-analyses increases the power, but the significant heterogeneity between the published studies on the treatment of chondral lesions in the knee precluded pooling the results of the individual studies in many cases, and/or performing subgroup analyses to determine the optimal procedure to the patient according to the lesion size, type of activity, comorbidity, and other characteristics. Few authors cautiously pooled the results of studies into meta-analyses, but these have to be interpreted with caution as the results of a meta-analysis are as good as the quality of the studies it includes.

ACI versus microfracture (MF): Mundi and colleagues (2015) (Evidence Table 1), performed a systematic review and meta-analysis of RCTs to compared ACI, MF, and OAT. The authors could only pool the results of the studies comparing ACI versus marrow stimulation (MS), mainly using the microfracture (MF) technique. The meta-analysis had valid methodology and analysis, but the included studies had their limitations, and were significantly
groups of patients would benefit more from each procedure. Vanlauwe J, and colleagues (2011) published 5-year
underwent. Knutsen and colleagues' (2007) long-term follow-up results of the RCT that compared first generation
by age (at 35 years cutoff), and that females had more treatment failures irrespective of the procedure they
those treated in less than 3 years from onset of symptoms). Subgroup analyses showed no significant differences
procedures are complementary, and that large RCTs with long-term follow-up are needed to determine which
first and third generations. The first analysis showed a small statistically insignificant difference between MF
improvement with ACI after the first generation study (Knutsen et al, 2007) was excluded. The authors noted
however, that the observed statistically significant difference was clinically irrelevant. They indicated that the two
the knee. The study had 90% power to detect a significant difference in the success rate between the two
techniques. The first article reporting the results of one-year follow up showed significant clinical improvement with
the two techniques when compared to baseline. There were no significant differences between the two procedures
outcomes, radiological outcomes, or treatment failures. However, the latter tended to occur earlier with MF (in
in the short-term, but ACI has superior outcomes on the long-term. Patients undergoing OAT were more likely to
reoperation due to lack of healing) in each of the treatment groups at 5 years compared to only 2.5% failures in
improvement after equal follow-up periods. The review included 7 RCTs and 2 observational studies with at least one year
follow-up. The meta-analysis had some disadvantages which may limit generalization of its results. It included a
small number of studies with relatively small population sizes, and the authors pooled the results of the RCTs
together with the observational studies that used different scores and values for assessing the outcomes. They
performed two meta-analyses: the first included all three ACI generations, and the second only included the
second and third generations. The first analysis showed a small statistically insignificant difference between MF
and all three ACI generations combined after 1 year, and the second meta-analysis showed a significant
improvement with ACI after the first generation study (Knutsen et al, 2007) was excluded. The authors noted
however, that the observed statistically significant difference was clinically irrelevant. They indicated that the two
procedures are complementary, and that large RCTs with long-term follow-up are needed to determine which
groups of patients would benefit more from each procedure. Vanlauwe J, and colleagues (2011) published 5-year
follow up results of an earlier study (Saris et al, 2008) that compared ACI using characterized chondrocyte
implantation (CCI) (ChondroCelect, Belgium) vs. MF in 118 patients with a single symptomatic cartilage defect in
the knee. The study had 90% power to detect a significant difference in the success rate between the two
techniques. The first article reporting the results of one-year follow up showed significant clinical improvement with
the two techniques when compared to baseline. There were no significant differences between the two procedures
in the short-term clinical outcomes or complication rates, but the tissue regenerate was superior with ACI. The
published 5-year results showed that the clinical improvements reported at 12 months and 24 months were
maintained for the duration of follow up. There were no significant differences between the two groups in clinical
outcomes, radiological outcomes, or treatment failures. However, the latter tended to occur earlier with MF (in
those treated in less than 3 years from onset of symptoms). Subgroup analyses showed no significant differences
by age (at 35 years cutoff), and that females had more treatment failures irrespective of the procedure they
underwent. Knutsen and colleagues' (2007) long-term follow-up results of the RCT that compared first generation
of ACI vs. MF (published in 2004 and reviewed earlier by MTAC) showed no significant difference between the two
techniques in the clinical or radiological outcomes at 5 years posttreatment. There was a 23% failure rate (need for a
reoperation due to lack of healing) in each of the treatment groups at 5 years compared to only 2.5% failures in
the MF and 5% with ACI at 2 years. Younger patients (<30 years of age) had better outcomes than older patients
irrespective of the treatment group. One third of the patients had radiographic evidence of early osteoarthritis at 5
years. The authors noted that the study was limited by only including patients with chronic symptomatic cartilage
defect of the knee, and by the lack of a control group that did not undergo surgical treatment or who were simply
treated with arthroscopic lavage. The authors concluded that further long-term follow-up is needed to determine if
one method is superior to the other, and to study the progression of osteoarthritis. ACI versus Osteochondral
autograft transplantation (OAT) Li et al, 2015 (Evidence Table 3) performed a systematic review and meta-
analyses of RCTs to compare the efficacy of OAT versus ACI in the treatment of large cartilage defects of the knee.
The analysis included 5 relatively small trials two of which evaluated the same cohort at different time
periods. There were differences between the studies in the surgical techniques and scoring of outcomes. The
authors quantified the results into crude grades for comparisons. The overall pooled results of the trials, after
performing a sensitivity analysis suggest that there were no significant differences between OAT and ACI results
in the short-term, but ACI has superior outcomes on the long-term. Patients undergoing OAT were more likely to
have worse conditions on the long-term when compared to those receiving ACI. The authors explained that the
injuries for autografts in OAT, the absence of fill and difference in orientation may influence the patient outcomes and
limit further OAT procedures. On the other hand ACI can be performed repeatedly in the same patient using
tissue engineered material. Clave, et al (2016), randomized 55 patients with isolated symptomatic femoral
osteochondral defects 2.5-7.5 cm² to receive Cartipatch (third generation ACI) or mosaicplasty (OAT). Patients
were followed-up for 2 years, and the primary outcome measure was the change in the functional outcome from
baseline to month 24 postoperatively. This was subjectively measured by International Knee Documentation
Committee (IKDC) score. The investigators could only recruit 55 of the 76 (72%) patients needed to provide
sufficient power, 15% of those randomized were lost to follow-up, and only 54% were included in the analysis. The authors indicated that contrary to the hypothesis of the study, the results showed that mosaicplasty was superior to Cartipatch in improving IKDC score 2 years after surgery. The significant difference between the two procedures was observed for defects measuring ≥ 3.5 cm². No significant difference was observed for smaller lesions. The trial was randomized and controlled, but had several disadvantages that would limit generalization of its results. It was small in size, the patients were not blinded to the procedure they underwent, only 55% of those randomized were included in the analysis, the outcome was subjective, and the follow-up duration was insufficient to determine the long-term outcomes of the interventions. Bentley and colleagues, 2012 (included in Li et al’s 2015 meta-analysis discussed earlier) published 10-year results of an earlier RCT that compared ACI to mosaicplasty among 100 patients with chronic lesions. The mean articular cartilage lesion size was 440.9 mm² (range 100-1050 mm²) in the ACI group, and 399.6 mm² (100-2000 mm²) in the mosaicplasty group. The early results of the trial showed significantly better outcome with ACI at 18 months post-surgery. This has been sustained over the years. At ten years, the functional outcome was significantly better with ACI vs. mosaicplasty when measured by the Cincinnati score, but insignificant with Stanmore-Bentley score. It is to be noted however, that only 15 of 48 patients randomized to OAT were included in the 10-year assessment of function. The failure rate (needed revision operations) was significantly higher in the mosaicplasty group vs. the ACI group (55% and 17% respectively). The pattern of failure was different; the ACI showed a low steady failure rate across 10 years, while the mosaicplasty group remained relatively satisfactory for the first 2 years then experienced a steep failure rate over the next 2 years. ACI versus any other treatment for articular cartilage lesions Vasiliadis and colleagues, 2010 conducted a systematic review of RCTs and quasi-randomized trials to compare ACI with any other type of treatment (including no treatment or placebo). The authors could not pool the results into a meta-analysis due to the clinical and methodological heterogeneity between the studies. They concluded that the studies show that ACI is an effective treatment for full thickness chondral defects and associated with improvement in clinical outcomes compared to baseline. The published evidence however, does not suggest any superiority of ACI over other treatments; complications rates were comparable between the different interventions except with an increased graft hypertrophy with ACI-P (the first generation ACI). Mundi and colleagues (2015) (Evidence Table 1), systematic review and meta-analysis of RCTs (discussed earlier) compared ACI, marrow stimulation (MS mainly using MF), and OAT to determine whether a single technique has superior outcomes at an intermediate follow-up period. The review included 11 RCTs (published through April 2014) with a total of 765 patients. 5 trials compared ACI vs MS, 3 compared ACI vs. OAT, and 3 evaluated different generations of ACI. The authors could only pool the results of the RCTs comparing ACI versus MS and found no significant difference between the two procedures in improving function or reducing pain at intermediate term follow-up. They indicated that ACI, MS, and OAT are all generally efficacious in improving symptoms in patients with focal knee cartilage defects, The authors pointed to the limitations and heterogeneity of the published studies and noted that the current best evidence does not show that any of the three techniques is superior to the others in improving the intermediate-term pain and function. They concluded that high quality studies with sufficient power and long-term outcomes are needed before any specific intervention is recommended over others. Samsudin and Kamural (2015) conducted a systematic review to compare different generations of ACI to other treatment modalities. Like many other researchers, they could not pool the results of the trials into a meta-analysis due to the heterogeneity between the studies. They concluded that the literature shows a trend towards similar outcomes when comparing ACI generations with other repair techniques, and that there is insufficient evidence to conclude that that ACI and it newer generations are more effective than other techniques in in repairing articular cartilage defects of the knee. Conclusion: There is insufficient published evidence from adequately powered large RCTs with valid methodology and long-term follow-up duration to determine that ACI and its newer generations are superior to other surgical techniques in repairing articular defects of the knee. The variations between the published studies make it difficult to accurately compare one intervention versus another or to determine the optimal procedure and technique for the individual patient. The literature suggests, but does not provide sufficient evidence that the newer generations of ACI may be associated with better long-term outcomes compared to microfracture in patients with larger full thickness, focal chondral defects in the knee. Articles: The literature search revealed a large number of experimental and observational studies on autologous chondrocyte implantation. Several small randomized controlled studies compared one or more generation ACI with MF, with OAT, or versus another ACI generation. The search also identified a number of systematic reviews with or without meta-analyses on ACI compared to one or more of the other treatment modalities. The more recent meta-analysis comparing ACI with microfracture (Negrin, 2013), a meta-analysis comparing ACI to OAT (Li, 2015), an analysis comparing all three procedures (Mundi, 2015) were selected for critical appraisal. Studies comparing one generation ACI to another generation were excluded from the review. Mundi R, Bedi A, Chow L, Crouch S3 Cartilage Restoration of the Knee: A Systematic Review and Meta-Analysis of Level 1 Studies. Am J Sports Med. 2015 Jul 2. pii: 0363546515589167. See Evidence Table. Negrin LL, Vécsei V. Do meta-analyses reveal time-dependent differences between the clinical outcomes achieved by microfracture and autologous chondrocyte implantation in the treatment of cartilage defects of the knee? Orthop Sci. 2013 Nov; 18(6):940-948. See Evidence
The use of Autologous Chondrocyte Implantation (Autologous Chondrocyte Transplantation) For the Treatment of Chondral Defects in the Knee does not meet the Kaiser Permanente Medical Technology Assessment Criteria.

<table>
<thead>
<tr>
<th>Date Created</th>
<th>Date Reviewed</th>
<th>Date Last Revised</th>
</tr>
</thead>
<tbody>
<tr>
<td>11/1998</td>
<td>11/11/1998⁹ MPC, 02/14/2001⁹ MPC, 04/17/2003⁹ MPC, 07/14/2004⁹ MPC, 06/05/06⁹ MPC, 07/07/2015⁹ MPC, 05/03/2016⁹ MPC, 03/07/2017⁹ MPC, 01/09/2018⁹ MPC, 11/06/2018⁹ MPC</td>
<td>04/05/2016</td>
</tr>
</tbody>
</table>

⁹ MPC Medical Policy Committee

**Revision History**

<table>
<thead>
<tr>
<th>Date</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>04/05/2016</td>
<td>Added MTAC review</td>
</tr>
<tr>
<td>11/22/2017</td>
<td>Added language to use Non-Medicare language for Medicare</td>
</tr>
</tbody>
</table>

**Codes**

- CPT: 27412
- HCPCS: J7330, S2112

---